The FDA's expanding embrace of new approach methodologies (NAMs) is forcing pharmaceutical manufacturing and quality teams to rethink how preclinical and CMC data will be generated, validated, and ...
This article examines how modern automation platforms create the digital foundation required for Pharma 4.0 by integrating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results